Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has revised its pharmaceutical contract manufacturing agreement with Eli Lilly, increasing the total contract value by KRW 256.2B from KRW 327.8B to KRW 584.1B upon customer request.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Change in contract value upon customer request
- Contract Title: Contract Manufacturing Agreement for Pharmaceutical Products
- Counterparty: Eli Lilly Kinsale Limited
- Pre-correction Contract Amount: KRW 327,826,300,620 (28.14% of Recent Annual Revenue) / USD 268,842,300
- Post-correction Contract Amount: KRW 584,071,016,620 (50.14% of Recent Annual Revenue) / USD 478,982,300
- Increased Value: KRW 256,244,716,000 (USD 210,140,000 increase)
- Recent Annual Revenue: KRW 1,164,776,873,641 (Based on 2020 consolidated financial statements)
- Initial Contract Date: December 20, 2019
- Initial Disclosure Date: March 28, 2022 (Applied Exchange Rate: USD/KRW 1,219.40)
- Contract Period: December 20, 2019 ~ December 31, 2029
- Other Remarks: Contract end date is subject to change based on mutual agreement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Revenue Recognition and Contract Terms Following Value Increase
This disclosure update reports a substantial increase in the contract manufacturing agreement originally signed in 2019, driven by a client request. Because contract details and completion dates remain subject to mutual agreement, tracking how this increased contract value is recognized in actual revenue over time is essential. Verifying this progress helps investors understand the concrete financial impact of the updated contract terms on financial statements. Relevant developments can be verified through subsequent Quarterly, Half-Yearly, and Annual Reports, as well as notes to financial statements.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
